Ueyama Hideki, Minoda Yukihide, Sugama Ryo, Ohta Yoichi, Nakamura Suguru, Takemura Susumu, Nakamura Hiroaki
Department of Orthopedic Surgery, Osaka City University Graduate School of Medicine, 1-4-3 Asahimachi, Abeno, Osaka, Japan.
Department of Orthopedic Surgery, Osaka City University Graduate School of Medicine, 1-4-3 Asahimachi, Abeno, Osaka, Japan.
Knee. 2020 Jun;27(3):767-776. doi: 10.1016/j.knee.2020.04.011. Epub 2020 May 28.
Peri-prosthetic bone mineral density (BMD) decreases after total knee arthroplasty (TKA). We aimed to specifically compare peri-prosthetic BMD changes between mobile- and fixed-bearing prostheses in patients undergoing oral bisphosphonate therapy, hypothesizing that mobile-bearing components would have a favorable effect on postoperative peri-prosthetic BMD.
This prospective cohort study investigated 30 patients who underwent simultaneous bilateral TKA for primary knee osteoarthritis between December 2007 and September 2012. All patients underwent mobile-bearing TKA in one knee and fixed-bearing TKA in the other and received oral alendronate therapy at a dosage of 35 mg/week. Peri-prosthetic and lumbar spine BMDs were measured using dual X-ray absorptiometry scans, with peri-prosthetic BMD changes being compared between the two prostheses in each patient at six months and one, two, three, and five years post-operation.
Clinical results did not significantly differ between two prostheses. Relative change of lumbar spine BMD was significantly greater at five years post-operation than at one year post-operation (p = 0.01), and was significantly correlated at five years post-operation with peri-prosthetic BMD in the central femur (r = 0.39, p = 0.002), posterior femur (r = 0.39, p = 0.002), and medial tibia (r = 0.42, p = 0.007).
There was no difference in peri-prosthetic BMD changes between two prostheses in patients undergoing oral bisphosphonate therapy. Our results suggest that the influence of oral bisphosphonate therapy might offset the influence of prosthetic design. Thus, oral bisphosphonate therapy may be more effective than prosthetic design selection in preventing post-TKA peri-prosthetic BMD loss.
II.
全膝关节置换术(TKA)后假体周围骨密度(BMD)会下降。我们旨在特别比较接受口服双膦酸盐治疗的患者中,活动平台和固定平台假体之间假体周围骨密度的变化,假设活动平台部件对术后假体周围骨密度有有利影响。
这项前瞻性队列研究调查了2007年12月至2012年9月期间因原发性膝关节骨关节炎同时接受双侧TKA的30例患者。所有患者一侧膝关节接受活动平台TKA,另一侧接受固定平台TKA,并接受每周35毫克的阿仑膦酸钠口服治疗。使用双能X线吸收法扫描测量假体周围和腰椎的骨密度,比较每位患者术后6个月、1年、2年、3年和5年时两种假体之间假体周围骨密度的变化。
两种假体的临床结果无显著差异。腰椎骨密度的相对变化在术后5年显著大于术后1年(p = 0.01),且在术后5年与股骨中段(r = 0.39,p = 0.002)、股骨后侧(r = 0.39,p = 0.002)和胫骨内侧(r = 0.42,p = 0.007)的假体周围骨密度显著相关。
接受口服双膦酸盐治疗的患者中,两种假体之间假体周围骨密度变化无差异。我们的结果表明,口服双膦酸盐治疗的影响可能抵消假体设计的影响。因此,在预防TKA术后假体周围骨密度丢失方面,口服双膦酸盐治疗可能比假体设计选择更有效。
II级。